email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

Research ArticleOpen Access

Intravitreal Injection of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion Volume 3 - Issue 1

Sara A Elbadi, Walid M Gaafar, Mohamed S Elwan, Asaad A Ghanem*

  • Mansoura Ophthalmology Center, Faculty of Medicine, Mansoura University, Egypt

Received: July 01, 2020;   Published: July 08, 2020

Corresponding author: Asaad A. Ghanem, Mansoura Ophthalmic Center , Faculty of Medicine, Mansoura University, Mansoura, Egypt

DOI: 10.32474/TOOAJ.2020.03.000153


Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF


Aim: This study aimed to evaluate the safety and efficacy of intravitreal Ranibizumab 0.5mg in the treatment of macular edema secondary to retinal vein occlusion.

Patients & Methods: This was a prospective interventional analytical study included 39 eyes of 39 patients with retinal vein occlusion. Ophthalmic examination included assessment of visual acuity, measurement of intraocular pressure, and fundus examination. All patients were scanned using Swept source optical coherence tomography (3D DRI OCT Triton [plus], Topcon Corporation, Tokyo, Japan) to assess central macular thickness. The changes of visual acuity, IOP, and central macular thickness were assessed. Data were analyzed via Kolmogorov-Smirnov test and Wilcoxon signed rank.

Results: The mean age was 56.56 ± 9.6, 48.7% were male and 51.3% were females. Hypertension was detected in 69.2%, and hyperlipidemia in 2.6%. The mean best corrected visual acuity was 1.5 logMAR, 1.00 logMAR,1.00 logMAR, preoperative, fourth month, six months postoperative, respectively, (p<0.001). The mean central macular thickness was 675 μ, 306 u, 264 u, preoperative, fourth month, six months postoperative, respectively, (p< 0.001). The OP was 16.5 mmHg, 16.9 mmHg, 17.1 mmHg, preoperative, fourth month, six months postoperative, respectively, (p=0.423). There were no observed significant ocular adverse events such as ocular inflammation, sterile and infectious endophthalmitis, or sustained increase in intraocular pressure with the use of intravitreal ranizumab injections.

Conclusion: Intravitreal Ranibizumab injections as monotherapy have shown promising results with BCVA improvement and a decrease of central macular thickness in patients with macular edema secondary to retinal vein occlusion.

Keywords: Ranibizumab; Macular Thickness; OCT; Visual Acuity

Abstract| Introduction| Patients and Methods| Swept Source OCT Imaging| Intravitreal Injection of Ranibizumab| Follow Up| Result| Ocular side effects| Discussion| Declarations| References|